LSD1 inhibition by tranylcypromine hydrochloride reduces alkali burn-induced corneal neovascularization and ferroptosis by suppressing HIF-1α pathway

Qian Deng, Yuelan Gao, Yujin Wang, Jiewen Mao, Yulin Yan, Zixian Yang, Yuyu Cong, Yanning Yang, Shanshan WanFrontiers in Pharmacology 2024 · DOI

TL;DR

Researchers have discovered that inhibiting the enzyme LSD1 with tranylcypromine hydrochloride (TCP) significantly reduces vision-threatening blood vessel growth and cell death in the cornea following chemical burns. This protective effect works by suppressing the HIF-1α signaling pathway, identifying a promising new epigenetic target for treating severe ocular injuries.

What Problem Does This Paper Address?

The cornea is the transparent, avascular "window" of the eye. When it suffers a severe alkali burn, it often undergoes corneal neovascularization (CNV)—the pathological growth of new blood vessels into the clear tissue—and intense inflammation, both of which can lead to permanent blindness.

While we know that tumor growth often relies on similar vessel-growing mechanisms, the specific "epigenetic switches" that turn on these processes in the eye after a burn are not fully understood. This paper investigates the role of Lysine-specific demethylase 1 (LSD1), an enzyme that modifies histones to regulate gene expression. The authors specifically look at whether LSD1 drives CNV and a specialized form of iron-dependent cell death called ferroptosis, and whether blocking LSD1 can save the cornea.

Methods

The study employed a dual-model approach:

  • In Vivo: A mouse model of alkali-induced corneal injury (using 1M NaOH). Mice were treated with varying doses of tranylcypromine hydrochloride (TCP), a known LSD1 inhibitor, via subconjunctival injection.
  • In Vitro: Human umbilical vein endothelial cells (HUVECs) were subjected to hypoxia-reoxygenation (H/R) to simulate the low-oxygen environment of a damaged cornea.

The researchers used a suite of molecular biology techniques to track the results:

  • Imaging: Slit-lamp microscopy to grade corneal opacity and vessel growth.
  • Molecular Assays: Western blotting and qPCR to measure protein and mRNA levels of LSD1, HIF-1α, and inflammatory markers (IL-1β, IL-6, TNF-α).
  • Ferroptosis Tracking: Measuring reactive oxygen species (ROS), malondialdehyde (MDA), and ferrous ion ($Fe^{2+}$) levels, alongside markers like GPX4.
  • Pathway Verification: Using siRNA to "knock down" specific genes and the inhibitor AG490 to verify the involvement of the JAK2/STAT3 signaling pathway.

Datasets

As a laboratory biological study, this paper does not use large-scale public datasets. Instead, it generates primary data from:

  • Experimental groups of male C57BL/6 mice (n=20 per group).
  • Standardized HUVEC cell lines.
  • Newly generated qPCR primer sequences for LSD1, IL-1β, IL-6, TNF-α, and β-Actin.

Key Insights and Ideas

  • LSD1 is a "Burn Biomarker": The study found a direct correlation between the severity of corneal damage and the expression levels of LSD1. As the burn progressed toward peak neovascularization (Day 10), LSD1 levels rose significantly.
  • The Ferroptosis Connection: This is one of the first papers to clearly link LSD1 to ferroptosis in the context of corneal burns. Inhibiting LSD1 didn't just stop vessels from growing; it stopped the cells from "rusting" to death by reducing iron accumulation and lipid peroxidation.
  • The HIF-1α Axis: The researchers mapped the mechanism: LSD1 promotes the JAK2/STAT3 pathway, which in turn stabilizes HIF-1α (Hypoxia-inducible factor 1-alpha). HIF-1α is the master regulator that tells the body to grow new blood vessels (via VEGF) and triggers oxidative stress.
  • TCP as a Repurposed Tool: Tranylcypromine (TCP) is traditionally known as an antidepressant. Here, its secondary function as an LSD1 inhibitor is leveraged as a potent ocular therapeutic.

Key Results

  • Reduced Vessel Growth: Subconjunctival injection of 10 mg/kg TCP significantly decreased the area of CNV and improved corneal transparency scores compared to untreated burned mice ($p < 0.05$).
  • Anti-Inflammatory Effect: TCP treatment led to a marked decrease in the mRNA levels of pro-inflammatory cytokines TNF-α and IL-1β.
  • Restoration of Redox Balance: In the burn model, antioxidant indicators like SOD and GSH were depleted. TCP treatment reversed this, while simultaneously lowering the levels of the "death marker" MDA and excess $Fe^{2+}$.
  • Pathway Confirmation: When the researchers artificially overexpressed HIF-1α in the lab, the protective effects of LSD1 inhibition were lost. This confirmed that LSD1's damage is primarily mediated through the HIF-1α pathway.

Limitations and Future Work

The authors acknowledge a few key areas for further study:

  • Protein Interactions: While the link between LSD1 and HIF-1α is clear, the exact protein-protein interaction sites and the specific histone modification sites involved in this ocular context need more granular mapping.
  • Mechanism Depth: The specific mechanism by which the JAK2/STAT3 pathway regulates HIF-1α in the cornea requires further verification to define a "more explicit mechanism of action."
  • Clinical Translation: While TCP is an existing drug, this study used subconjunctival injections in mice. Future work would need to explore topical applications (like eye drops) and long-term safety profiles for human use in ophthalmic emergencies.

Summary updated

Abstract

These findings suggest that LSD1 inhibition via the HIF-1α-driven pathway prevents angiogenesis, oxidative stress, and ferroptosis in corneal alkali burn-induced CNV, highlighting LSD1 as a potential therapeutic target.
BibTeX
@inproceedings{deng2024lsd,
  author = {Qian Deng and Yuelan Gao and Yujin Wang and Jiewen Mao and Yulin Yan and Zixian Yang and Yuyu Cong and Yanning Yang and Shanshan Wan},
  title = {{LSD1 inhibition by tranylcypromine hydrochloride reduces alkali burn-induced corneal neovascularization and ferroptosis by suppressing HIF-1α pathway}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1411513},
}
Figure